/AZN
AZN Stock - AstraZeneca PLC
Healthcare|Drug Manufacturers - GeneralNASDAQ
$91.36+0.83%
+$0.75 (+0.83%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.83
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).81
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+15.5%upside
Target: $105.52
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AZN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$90.45 – $92.27
TARGET (TP)$105.50
STOP LOSS$84.05
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.17
52W High$94.02
52W Low$61.24
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $54.07B | $45.81B | $44.35B | $37.42B | $26.62B |
| Gross Profit | $43.87B | $37.54B | $31.96B | $24.98B | $21.32B |
| Gross Margin | 81.1% | 82.0% | 72.1% | 66.8% | 80.1% |
| Operating Income | $10.00B | $8.19B | $3.76B | $1.06B | $5.16B |
| Net Income | $7.04B | $5.96B | $3.29B | $112.00M | $3.20B |
| Net Margin | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% |
| EPS | $1.14 | $1.91 | $1.06 | $0.04 | $1.22 |
Company Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
45%
Hold / Neutral
8
36%
Sell / Underperform
4
18%
Analyst Consensus🔴 Bearish
10 Bullish12 Neutral/Bearish
Price Targets
$80
Average Target
↓ 12.2% Downside
Now
$70
Low
$80
Average
$97
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 27th 2025 | Jefferies | Resumed | Buy | - |
| October 16th 2025 | Deutsche Bank | Downgrade | Sell | - |
| April 15th 2025 | Exane BNP Paribas | Initiation | Outperform | $75 |
| February 13th 2025 | UBS | Upgrade | Buy | - |
| February 12th 2025 | Morgan Stanley | Initiation | Overweight | - |
| November 20th 2024 | UBS | Upgrade | Neutral | - |
| November 6th 2024 | Deutsche Bank | Upgrade | Hold | - |
| September 13th 2024 | Deutsche Bank | Downgrade | Sell | - |
| May 30th 2024 | Goldman | Initiation | Buy | $97 |
| April 16th 2024 | Deutsche Bank | Upgrade | Hold | - |
| February 8th 2024 | Deutsche Bank | Downgrade | Sell | - |
| January 23rd 2024 | Morgan Stanley | Initiation | Overweight | $85 |
| January 16th 2024 | UBS | Resumed | Sell | - |
| January 3rd 2024 | Jefferies | Downgrade | Hold | $70← $78.5 |
| December 18th 2023 | HSBC Securities | Initiation | Buy | $78 |
Earnings History & Surprises
AZNBeat Rate
61%
Last 18 quarters
Avg Surprise
+1.2%
EPS vs Estimate
Beats / Misses
11/6
1 met exactly
Latest EPS
$1.19
Q4 2025
EPS Surprise History
Q1 24
-7.6%
$0.73vs$0.79
Q2 24
-15.6%
$1.03vs$1.22
Q3 24
-17.5%
$0.99vs$1.20
Q4 24
+1.0%
$1.04vs$1.03
Q1 25
-1.9%
$1.05vs$1.07
Q2 25
+12.7%
$1.24vs$1.10
Q3 25
0.0%
$1.09vs$1.09
Q4 25
+4.4%
$1.19vs$1.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $1.09 | — | — | — |
Q4 2025 | Nov 6, 2025 | $1.14 | $1.19 | +4.4% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $1.09 | $1.09 | 0.0% | = MET |
Q2 2025 | Apr 29, 2025 | $1.10 | $1.24 | +12.7% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $1.07 | $1.05 | -1.9% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $1.03 | $1.04 | +1.0% | ✓ BEAT |
Q3 2024 | Jul 25, 2024 | $1.20 | $0.99 | -17.5% | ✗ MISS |
Q2 2024 | Apr 25, 2024 | $1.22 | $1.03 | -15.6% | ✗ MISS |
Q1 2024 | Feb 8, 2024 | $0.79 | $0.73 | -7.6% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $0.85 | $0.87 | +2.4% | ✓ BEAT |
Q3 2023 | Jul 28, 2023 | $0.95 | $1.08 | +13.7% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $1.07 | $0.96 | -10.3% | ✗ MISS |
Q1 2023 | Feb 9, 2023 | $0.67 | $0.69 | +3.0% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $0.72 | $0.84 | +16.7% | ✓ BEAT |
Q3 2022 | Jul 29, 2022 | $0.78 | $0.86 | +10.3% | ✓ BEAT |
Q2 2022 | Apr 29, 2022 | $0.86 | $0.95 | +10.5% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $0.77 | $0.84 | +9.1% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $0.63 | $0.54 | -14.3% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $0.43 | $0.45 | +4.7% | ✓ BEAT |
Latest News
Shars of drug companies are higher after announcing deals with President Trump for lower drug prices.
📈 PositiveBenzinga•Dec 19, 2025, 08:34 PM•Also: , ,
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralBenzinga•Dec 19, 2025, 07:30 PM•Also: , ,
FDA Says On Dec 18, Said It Got Postmarketing Safety Data On Thromboembolic Events, Including Serious & Fatal Outcomes, In Patients Treated With Andexxa; Astrazeneca Submitted Request To Voluntarily Withdraw BLA For Andexxa For Commercial Reasons; Based On Available Data, FDA Considers Risks Of Andexxa To Outweigh Its Benefits; Andexxa Will No Longer Be Manufactured For Or Sold In U.S. By Astrazeneca After Dec 22, 2025
📉 NegativeBenzinga•Dec 19, 2025, 03:04 PM
Daiichi Sankyo And AstraZeneca's DATROWAY EU Application Validated For First Line Metastatic TNBC Without Immunotherapy Option Supported By TROPION-Breast02 OS And PFS Improvements
📈 PositiveBenzinga•Dec 18, 2025, 07:42 AM•Also:
Compugen rises on royalty deal with AstraZeneca
📈 PositiveSeeking Alpha•Dec 17, 2025, 12:58 PM•Also:
Nuvectis Pharma Initiated Phase 1b Study Of NXP900 In Combination With Astrazeneca's Tagrisso (Osimertinib) In Patients With EGFRmut+ NSCLC
📈 PositiveBenzinga•Dec 17, 2025, 12:09 PM•Also:
Compugen Agrees With AstraZeneca To Monetize Portion Of Compugen's Rilvegostomig Future Royalties
📈 PositiveBenzinga•Dec 17, 2025, 12:03 PM•Also:
CORRECTION: FDA Approves Fam-trastuzumab Deruxtecan-nxki With Pertuzumab For Unresectable Or Metastatic HER2-Positive Breast Cancer
📈 PositiveBenzinga•Dec 15, 2025, 09:34 PM
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki With Pertuzumab For Unres
📈 PositiveBenzinga•Dec 15, 2025, 06:40 PM
Reuters Issues Correction: U.S. FDA Says "Doing A Thorough Investigation, Across Multiple Age Groups, Of Deaths Potentially Related To Covid Vaccines"
📉 NegativeBenzinga•Dec 9, 2025, 08:54 PM•Also: , ,
Daiichi Sankyo Says First Patient Dosed In Randomization Phase Of DESTINY-Ovarian01 Phase 3 Trial Evaluating ENHERTU, Jointly Developed, Commercialized By Daiichi And AstraZeneca, In Patients With HER2 Expressing Advanced Ovarian Cancer
📈 PositiveBenzinga•Dec 9, 2025, 12:14 PM•Also:
AstraZeneca Selects Salesforce's Agentforce Life Sciences To Power Global AI-Driven Customer Engagement
📈 PositiveBenzinga•Dec 4, 2025, 09:02 PM•Also:
The FDA Has Accepted Astrazeneca's New Drug Application For Baxdrostat For Patients With Hard-to-control Hypertension As An Add-on To Other Antihypertensive Medicines, The Prescription Drug User Fee Act Date Is Anticipated During Q2 Of 2026 Following Use Of A Priority Review Voucher
📈 PositiveBenzinga•Dec 2, 2025, 12:34 PM
FDA Approves AstraZeneca's IMFINZI Combo For Early Stomach And GEJ Cancers
📈 PositiveBenzinga•Nov 26, 2025, 12:06 PM
AstraZeneca Gets Approval For Imfinzi In U.S. To Treat Resectable, Early-Stage And Locally Advanced Gastric And Gastroesophageal Junction Cancers
📈 PositiveBenzinga•Nov 25, 2025, 06:35 PM
'AstraZeneca Plans $2B Manufacturing Investment In Maryland; New Capacity At Fredrick And Gaithersburg Facilities To Accelerate Production Of Cancer, Rare & Chronic Disease Medicines; Investment To Support 2,600 Jobs Across Two Sites In State And Creation Of 300 Skilled Jobs; Frederick Facility Expected To Be Operational In 2029; Gaithersburg Facility To Be Fully Operational By 2029' - Washington Business Journal
📈 PositiveBenzinga•Nov 21, 2025, 07:03 PM
VIPC Signs MOU With AstraZeneca, Eli Lilly, Merck To Develop The Virginia Center For Advanced Pharmaceutical Manufacturing To Train Workforce Of The Future; Partnership Commits $120M Of Workforce Investment From AstraZeneca, Lilly, And Merck
📈 PositiveBenzinga•Nov 20, 2025, 04:41 PM•Also: ,
FDA Approves Selumetinib For Adults With Neurofibromatosis Type 1 With Symptomatic, Inoperable Plexiform Neurofibromas
📈 PositiveBenzinga•Nov 19, 2025, 03:08 PM
Reported Earlier, AstraZeneca Highlights Baxdrostat's 14.0 MmHg Ambulatory SBP Drop And 13.9 MmHg Night-Time Benefit With Odds Ratio 15.2 For Target Achievement At Week 12
📈 PositiveBenzinga•Nov 10, 2025, 07:29 AM
NATRON Phase III Trial Shwed AstraZeneca's FASENRA Demonstrated Statistically Significant Delay In First Worsening Or Time To Fare In Hypereosinophilic Syndrome
📈 PositiveBenzinga•Nov 7, 2025, 02:01 PM
Frequently Asked Questions about AZN
What is AZN's current stock price?
AstraZeneca PLC (AZN) is currently trading at $91.36 per share. The stock has moved +0.83% today.
What is the analyst price target for AZN?
The average analyst price target for AZN is $105.50, based on 1 analyst.
What sector is AstraZeneca PLC in?
AstraZeneca PLC operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NASDAQ exchange.
What is AZN's market cap?
AstraZeneca PLC has a market capitalization of $283.27 billion, making it a mega-cap company.
Does AZN pay dividends?
No, AstraZeneca PLC does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABBV
AbbVie Inc.
$226.72
Mkt Cap: $400.7B
AMGN
Amgen Inc.
$327.38
Mkt Cap: $176.3B
BMY
Bristol-Myers Squibb Company
$54.19
Mkt Cap: $110.3B
GILD
Gilead Sciences, Inc.
$124.29
Mkt Cap: $154.2B
GSK
GSK plc
$48.61
Mkt Cap: $98.8B
JNJ
Johnson & Johnson
$206.37
Mkt Cap: $497.2B
LLY
Eli Lilly and Company
$1071.44
Mkt Cap: $962.5B
MRK
Merck & Co., Inc.
$101.09
Mkt Cap: $254.1B
NVS
Novartis AG
$136.06
Mkt Cap: $266.2B
PFE
Pfizer Inc.
$25.20
Mkt Cap: $143.3B
Explore stocks similar to AZN for comparison